Founded in 2018, Xellera Therapeutics operates Hong Kong’s first commercial cGMP facilities for cell and gene therapies, offering a full CDMO platform—process development, custom manufacturing, bioanalytical testing, and cryostorage—compliant with US FDA, EMA and PIC/S standards to support ATMP innovation in Asia. https://www.xelleratherapeutics.com/